-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since most type 2 diabetes (T2D) patients are treated in primary care, primary care clinicians play a key role in optimizing diabetes management
The improvement and maintenance of glucose control is related to stronger compliance with hypoglycemic therapy.
Primary endpoint: the time between two scheduled consecutive follow-ups after the 26th week to insufficient blood glucose control (HbA1c> 7.
Results: Among the randomized patients (liraglutide, n=996; OAD, n=995), 47.
The median time of poor glycemic control in patients with liraglutide was 44 weeks and 65 weeks compared with OAD.
Figure 1 OAD, 4.
Figure 1 OAD, 4.
Table 1 The duration of treatment with liraglutide and OAD and the duration of premature discontinuation
Table 1 The duration of treatment with liraglutide and OAD and the duration of premature discontinuationTable 2 Changes in clinical variables from baseline at 104 weeks or when treatment is stopped prematurely
Table 2 Changes in clinical variables from baseline at 104 weeks or when treatment is stopped prematurelyTable 3 Treatment of emergency serious adverse events (SOC and ≥1% of patients in any group)
Table 3 Treatment of emergency serious adverse events (SOC and ≥1% of patients in any group)
Figure 2 Kaplan-Meier time chart of liraglutide treatment to insufficient blood glucose control and post-event OAD subgroup*
Figure 2 Kaplan-Meier time chart of liraglutide treatment to insufficient blood glucose control and post-event OAD subgroup*
Compared with OAD, liraglutide can better maintain blood sugar control and supports the use of liraglutide in intensive treatment of T2D patients
Unger J, Allison DC, Kaltoft M, et al.
Maintenance of Glycemic Control with Liraglutide versus Oral Antidiabetic Drugs as Add-on Therapies in Patients with Type 2 Diabetes Uncontrolled with Metformin Alone: A Randomized Clinical Trial in Primary Care (LIRA-PRIME).
Leave a message here